

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that the Company's actual future results or performance may be materially different from what the Company expects. In this announcement, statements of, or references to, the intentions of the Company and/or any of its directors are made as of the date of this announcement. Any of these intentions may alter in light of future development.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT

EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that AIM Kanghuai Biopharmaceutical (Jiangsu) Co., Ltd. (艾美康淮生物製藥(江蘇)有限公司), a wholly-owned subsidiary of the Company, has recently obtained the clinical trial approval for the EV71-CA16 bivalent HFMD vaccine candidate issued by the Center for Drug Evaluation of National Medical Products Administration.

Hand, foot and mouth disease (HFMD) is a common disease among children below 5 years old in the People's Republic of China. Within 1 to 2 days after infection, skin rash can usually be found on the palms, soles and mouth, and blisters may be found on the tongue and gums. Serious HFMD may lead to onychomadesis (separation of fingernails and toenails) within weeks after infection. Viruses causing HFMD are usually transmitted through person-to-person contact, infected patients' cough and excretion and objects contaminated by the viruses. The most common pathogens of HFMD are two subtypes of enterovirus, namely the enterovirus 71 (EV71) and Coxsackievirus type A16 (CA16).

The Group's EV71-CA16 bivalent HFMD vaccine candidate simultaneously targets the EV71 and CA16 viral strains, which can enhance protection against HFMD.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, October 31, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.